IDEAS home Printed from
MyIDEAS: Log in (now much improved!) to save this paper

International Experience With Pharmaceutical Policy: Common Challenges and Lessons for Canada

Listed author(s):
  • Donald Willison


    (Department of Clinical Epidemiology & Biostatistics, McMaster University, Centre for Evaluation of Medicines)

  • Mary Wiktorowicz

    (Department of Clinical Epidemiology & Biostatistics, and Political Science, University of Western Ontario)

  • Paul Grootendorst

    (Department of Clinical Epidemiology & Biostatistics, McMaster University, Centre for Evaluation of Medicines)

  • Bernie O'Brien

    (Department of Clinical Epidemiology & Biostatistics, McMaster University, Centre for Evaluation of Medicines)

  • Mitchell Levine

    (Department of Clinical Epidemiology & Biostatistics, McMaster University, Centre for Evaluation of Medicines)

  • Raisa Deber

    (Department of Health Administration, University of Toronto)

  • Jeremiah Hurley


    (Department of Clinical Epidemiology & Biostatistics, Centre for Health Economics and Policy Analysis, McMaster University)

Pharmaceuticals are the focus of increased scrutiny by public insurers. Between 1985 and 1998, drug expenditure in Canada increased by 226% - approximately double the increase in total expenditure on health. Prescribed and non-prescribed drugs now comprise the second-largest share of health care expenditures after hospitals, surpassing physicians’ services. The National Forum on Health called for common strategies across the provinces, to manage pharmaceuticals from a health policy perspective. At the same time, the federal government and several provinces are interested in promoting pharmaceutical research and development (R&D), as part of the advancement of a knowledge-based economy. In the past, debates about pharmaceutical policy centred on the balancing of cost-containment and access to needed pharmaceuticals. The creation of an environment more conducive to attracting pharmaceutical R&D introduces additional tensions that will, no doubt, require concessions in current policies to manage pharmaceutical expenditures. In addition, a significant R&D investment will have predictable “downstream” effects on other sectors, such as academic research. In this study, we describe the experience of 7 Western industrialized countries in controlling pharmaceutical budgets while maintaining access to medically necessary prescription medications. In addition, we describe the potential impact of these policies on pharmaceutical R&D and the efforts of these countries to create a favourable climate for fostering R&D within their borders. We identify tensions that arise between health policy and industrial policy goals, and broad questions of directions and choices.

If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.

File URL:
File Function: First version, 2001
Download Restriction: no

Paper provided by Centre for Health Economics and Policy Analysis (CHEPA), McMaster University, Hamilton, Canada in its series Centre for Health Economics and Policy Analysis Working Paper Series with number 2001-08.

in new window

Length: 66 pages
Date of creation: 2001
Handle: RePEc:hpa:wpaper:200108
Contact details of provider: Postal:
CRL Building, 282, 1280 Main Street West, Hamilton, Ontario L8S 4K1

Phone: (905) 525-9140, extension 22122
Fax: (905) 546-5211
Web page:

More information through EDIRC

No references listed on IDEAS
You can help add them by filling out this form.

This item is not listed on Wikipedia, on a reading list or among the top items on IDEAS.

When requesting a correction, please mention this item's handle: RePEc:hpa:wpaper:200108. See general information about how to correct material in RePEc.

For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Lyn Sauberli)

If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

If references are entirely missing, you can add them using this form.

If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.

If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.

Please note that corrections may take a couple of weeks to filter through the various RePEc services.

This information is provided to you by IDEAS at the Research Division of the Federal Reserve Bank of St. Louis using RePEc data.